These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2694814)

  • 41. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
    Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
    Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection.
    Wagner DK; Graham BS; Wright PF; Walsh EE; Kim HW; Reimer CB; Nelson DL; Chanock RM; Murphy BR
    J Clin Microbiol; 1986 Aug; 24(2):304-6. PubMed ID: 3755731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice.
    Routledge EG; Willcocks MM; Samson AC; Morgan L; Scott R; Anderson JJ; Toms GL
    J Gen Virol; 1988 Feb; 69 ( Pt 2)():293-303. PubMed ID: 3339327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Respiratory syncytial virus: virology, diagnosis, and vaccination.
    Toms GL
    Lung; 1990; 168 Suppl():388-95. PubMed ID: 1696677
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Viral vaccines for the prevention of childhood pneumonia in developing nations: priorities and prospects.
    Steinhoff MC
    Rev Infect Dis; 1991; 13 Suppl 6():S562-70. PubMed ID: 1650495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines.
    Watt PJ; Robinson BS; Pringle CR; Tyrrell DA
    Vaccine; 1990 Jun; 8(3):231-6. PubMed ID: 2363300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The immunization of adults against respiratory syncytial virus infection].
    Leshchinskaia NP; Korchanova NL; Pokrovskaia EE; Efremov BV; Padalko IuV
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Oct; (10):49-53. PubMed ID: 2609811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [From prevention to treatment of respiratory syncytial virus infections].
    Reinert P
    Pediatrie; 1991; 46(8-9 Suppl):10-3. PubMed ID: 1665220
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins.
    Walsh EE; Hall CB; Schlesinger JJ; Brandriss MW; Hildreth S; Paradiso P
    J Gen Virol; 1989 Nov; 70 ( Pt 11)():2953-61. PubMed ID: 2479715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection.
    Walsh EE; Hall CB; Briselli M; Brandriss MW; Schlesinger JJ
    J Infect Dis; 1987 Jun; 155(6):1198-204. PubMed ID: 3553346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccination against respiratory syncytial virus: problems and progress.
    Toms GL
    FEMS Microbiol Immunol; 1991 Oct; 3(5):243-56. PubMed ID: 1797047
    [No Abstract]   [Full Text] [Related]  

  • 52. Two distinct subtypes of human respiratory syncytial virus.
    Mufson MA; Orvell C; Rafnar B; Norrby E
    J Gen Virol; 1985 Oct; 66 ( Pt 10)():2111-24. PubMed ID: 2413163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus.
    Bourgeois C; Corvaisier C; Bour JB; Kohli E; Pothier P
    J Gen Virol; 1991 May; 72 ( Pt 5)():1051-8. PubMed ID: 2033389
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Respiratory syncytial virus: reverse genetics and vaccine strategies.
    Collins PL; Murphy BR
    Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical and epidemiologic aspects of respiratory syncytial virus antigenic variants in Argentinian children.
    Salomón HE; Avila MM; Cerqueiro MC; Orvell C; Weissenbacher M
    J Infect Dis; 1991 May; 163(5):1167. PubMed ID: 2019767
    [No Abstract]   [Full Text] [Related]  

  • 56. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice.
    Martinez X; Li X; Kovarik J; Klein M; Lambert PH; Siegrist CA
    Eur J Immunol; 1999 Oct; 29(10):3390-400. PubMed ID: 10540351
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection.
    Hussell T; Georgiou A; Sparer TE; Matthews S; Pala P; Openshaw PJ
    J Immunol; 1998 Dec; 161(11):6215-22. PubMed ID: 9834108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. T-cells in respiratory syncytial virus (RSV) infection.
    Askonas BA; Openshaw P; Cannon M
    Adv Exp Med Biol; 1989; 257():9-17. PubMed ID: 2533461
    [No Abstract]   [Full Text] [Related]  

  • 59. Evidence that the fusion protein of respiratory syncytial virus exists as a dimer in its native form. Brief report.
    Arumugham RG; Hildreth SW; Paradiso PR
    Arch Virol; 1989; 106(3-4):327-34. PubMed ID: 2774976
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers.
    Pringle CR; Filipiuk AH; Robinson BS; Watt PJ; Higgins P; Tyrrell DA
    Vaccine; 1993; 11(4):473-8. PubMed ID: 8470433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.